EFFECTS ON INTIMA MEDIA THICKNESS: ROSUVASTATIN 40 MG (METEOR)

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。这项研究旨在评估瑞舒伐他汀与安慰剂对心血管事件风险较低的无症状参与者颈动脉内膜-中层厚度(IMT)的影响。参与者的低密度脂蛋白-胆固醇将在130至189毫克/分升之间。这项研究将评估接受瑞舒伐他汀40 mg与安慰剂治疗2年的参与者的IMT变化是否随着时间的推移而有所不同。如果发现有显著差异，则将对瑞舒伐他汀受试者进行检查，以确定在治疗期间IMT是否有显著回落。中心实验室将进行所有的血脂测量。中心实验室还将进行安全实验室(化学板和验孕)。安全措施包括临床评估、患者监测和实验室评估。合规性将通过平板电脑数量进行监控。参与者可以接受降胆固醇药物治疗，并可能从参与这项活动中获得降低胆固醇和/或直接健康益处S

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This research study is designed to evaluate the effect of rosuvastatin versus placebo on carotid intima media thickness (IMT) in asymptomatic participants who are at low risk for cardiovascular events. Participants will have an LDL-cholesterol between 130 and 189 mg/dl. The study will assess whether there is a difference over time in the IMT change in participants who are treated for 2 years with rosuvastatin 40 mg versus placebo. If a significant difference is found, then the rosuvastatin subjects will be examined to determine whether there is significant regression in IMT during the treatment period. A central laboratory will perform all lipid measurements. The central laboratory will also perform safety labs (chemistry panels and pregnancy tests). Safety measurements are clinical evaluation, patient monitoring, and laboratory assessment. Compliance will be monitored by tablet count. Participants may receive cholesterol-lowering medication and may receive a reduction in cholesterol and/or direct health benefits from participation in this s